References
- BEXXAR prescribing information, GlaxoSmithKline.
- Horning SJ, Younes A, Jain V, et al.
Efficacy and safety of Tositumomab and Iodine I-131 Tositumomab (Bexxar) in B-cell lymphoma,
progressive after Rituximab. J Clin Oncol. 2005;23:712-719.
- Data on file, GlaxoSmithKline.
- Adapted with permission from the Society of Nuclear Medicine from Seldin DW. Techniques
for using Bexxar for the treatment of non-Hodgkin’s lymphoma. J Nucl Med Technol.
2002;30:109-114.
- Vose JM, Chiu BC, Cheson BD, Dancey J, Wright J. Update on epidemiology and therapeutics for non-Hodgkin's lymphoma. Hematology Am Soc Hematol Educ Program. 2002;1:241-262.
- US Nuclear Regulatory
Commission. Code of Federal Regulations: Title 10–Energy. Section 35.75. Release of
individuals containing unsealed byproduct material or implants containing byproduct material. http://www.nrc.gov/
reading-rm/doc-collections/cfr/part035/part035-0075.html. Accessed May 10, 2007.
- Rutar FJ, Augustine SC, Colcher D, et al. Outpatient treatment
with
131I-anti-B1 antibody: radiation exposure to family members. J Nucl Med. 2001;42:907-915.
Click here for Important Safety Information about BEXXAR
Click here for Detailed Safety Information
Complete Prescribing Information for
[ RETURN TO TOP ]
